Literature DB >> 32457046

Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs.

Brian Villalba1, Jiawen Li1, Kenneth A Johnson2.   

Abstract

NS5B is the RNA-dependent RNA polymerase that catalyzes the replication of the hepatitis C virus genome. It is a major target for antiviral drugs including nucleoside analogs, such as the prodrugs mericitabine and sofosbuvir, which get metabolized to 2'-fluoro-2'C-methylcytidine-5'-triphosphate and 2'-fluoro-2'C-methyluridine-5'-triphosphate, respectively. These analogs act as chain terminators after they are incorporated during RNA synthesis. Recently, it has been shown that NS5B can efficiently remove chain terminators by a nucleotide-mediated excision reaction that rescues RNA synthesis. In this study, we use transient-state kinetics to understand the efficiency of inhibition for five nucleoside analogs. We show that CTP analogs are readily incorporated into a growing primer by NS5B but are also efficiently excised. In contrast, although UMP analogs are more slowly incorporated, the excision of UMP is slow and inefficient, and modifications to the 2'-carbon of the UTP ribose ring further decreased rates of excision to an undetectable level. Taken together, these data suggest that the clinical effectiveness of sofosbuvir is largely a function of being intractable to nucleotide-mediated excision compared with similar nucleoside analogs.
© 2020 Villalba et al.

Entities:  

Keywords:  NS5B; RNA polymerase; antiviral drug; chain terminator; enzyme kinetics; hepatitis C virus (HCV); inhibition mechanism; mericitabine; nucleoside/nucleotide analogue; sofosbuvir; viral polymerase

Mesh:

Substances:

Year:  2020        PMID: 32457046      PMCID: PMC7383390          DOI: 10.1074/jbc.RA120.013422

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

2.  FitSpace explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data.

Authors:  Kenneth A Johnson; Zachary B Simpson; Thomas Blom
Journal:  Anal Biochem       Date:  2008-12-25       Impact factor: 3.365

3.  Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

Authors:  Evguenia S Svarovskaia; Hadas Dvory-Sobol; Neil Parkin; Christy Hebner; Viktoria Gontcharova; Ross Martin; Wen Ouyang; Bin Han; Simin Xu; Karin Ku; Sophia Chiu; Edward Gane; Ira M Jacobson; David R Nelson; Eric Lawitz; David L Wyles; Neby Bekele; Diana Brainard; William T Symonds; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  Clin Infect Dis       Date:  2014-09-28       Impact factor: 9.079

4.  Influence of neighboring bases on DNA polymerase insertion and proofreading fidelity.

Authors:  J Petruska; M F Goodman
Journal:  J Biol Chem       Date:  1985-06-25       Impact factor: 5.157

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.

Authors:  Polina German; Anita Mathias; Diana Brainard; Brian P Kearney
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

6.  Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

Authors:  Amy Fung; Zhinan Jin; Natalia Dyatkina; Guangyi Wang; Leo Beigelman; Jerome Deval
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

7.  L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

Authors:  Evguenia S Svarovskaia; Edward Gane; Hadas Dvory-Sobol; Ross Martin; Brian Doehle; Charlotte Hedskog; Ira M Jacobson; David R Nelson; Eric Lawitz; Diana M Brainard; John G McHutchison; Michael D Miller; Hongmei Mo
Journal:  J Infect Dis       Date:  2015-11-24       Impact factor: 5.226

Review 8.  Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.

Authors:  Matthias Götte; Jordan J Feld
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-05-05       Impact factor: 46.802

Review 9.  An overview of HCV molecular biology, replication and immune responses.

Authors:  Usman A Ashfaq; Tariq Javed; Sidra Rehman; Zafar Nawaz; Sheikh Riazuddin
Journal:  Virol J       Date:  2011-04-11       Impact factor: 4.099

10.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

Authors:  Michael J Sofia; Donghui Bao; Wonsuk Chang; Jinfa Du; Dhanapalan Nagarathnam; Suguna Rachakonda; P Ganapati Reddy; Bruce S Ross; Peiyuan Wang; Hai-Ren Zhang; Shalini Bansal; Christine Espiritu; Meg Keilman; Angela M Lam; Holly M Micolochick Steuer; Congrong Niu; Michael J Otto; Phillip A Furman
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

View more
  5 in total

1.  Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.

Authors:  Mona Seifert; Subhas C Bera; Pauline van Nies; Robert N Kirchdoerfer; Ashleigh Shannon; Thi-Tuyet-Nhung Le; Xiangzhi Meng; Hongjie Xia; James M Wood; Lawrence D Harris; Flavia S Papini; Jamie J Arnold; Steven Almo; Tyler L Grove; Pei-Yong Shi; Yan Xiang; Bruno Canard; Martin Depken; Craig E Cameron; David Dulin
Journal:  Elife       Date:  2021-10-07       Impact factor: 8.713

2.  Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase.

Authors:  Tyler L Dangerfield; Nathan Z Huang; Kenneth A Johnson
Journal:  iScience       Date:  2020-11-28

3.  Inhibition of SARS-CoV-2 polymerase by nucleotide analogs: a single molecule perspective.

Authors:  Mona Seifert; Subhas Chandra Bera; Pauline van Nies; Robert N Kirchdoerfer; Ashleigh Shannon; Thi-Tuyet-Nhung Le; Xiangzhi Meng; Hongjie Xia; James M Wood; Lawrence D Harris; Flávia S Papini; Jamie J Arnold; Steven C Almo; Tyler L Grove; Pei-Yong Shi; Yan Xiang; Bruno Canard; Martin Depken; Craig E Cameron; David Dulin
Journal:  bioRxiv       Date:  2021-04-08

4.  Rate-limiting pyrophosphate release by hepatitis C virus polymerase NS5B improves fidelity.

Authors:  Brian Villalba; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2020-09-16       Impact factor: 5.157

Review 5.  Hepatitis C Viral Replication Complex.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2021-03-22       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.